Foamix Ltd. and Therapeutics Inc. Enter into Joint Venture to Develop New Prescription Foams for Inflammatory Skin Diseases

US Grant for Foamix's Saccharide Foam Patent - Topical "Sweet Foam" Products for Wound & Burn Therapy

Foamix is a Finalist for the Red Herring 100 Global Award for Most Promising Technology Ventures

Dermatology co Foamix teams with Switzerland's Galderma

Foamix Expands International Patent Protection for its Emollient Foam Platform

Foamix Extends Collaboration with Galderma

Foamix Ltd. and VIB Sign Co-Development Agreement for Innovative Topical Therapy for Psoriasis

Promius Pharma, LLC Launches Scytera™ (Coal Tar) Foam 2% for Treatment of Psoriasis

Foamix is Finalist for International 2008 SCRIP Award

Ferndale and Foamix Execute License Agreement for Development of Non-Steroidal Foam for Atopic Dermatitis

Omnibus Survey:72% of Women Are Dissatisfied with Their Current Treament of Vaginal Infection

Foamix and Galderma to Develop Medicated Foam for Certain Skin Diseases

Foamix is a finalist for the Red Herring 100 Europe 2008 Award

BIRD invests $14m in 16 joint projects; English Hebrew

Foamix Announces New Foam Patent Approvals

Ferndale and Foamix Enter Development of an Innovative Foam for the Treatment of Atopic Dermatitis

Foamix Acquires Rights to Dual Chamber Aerosol Foam Technology

In-Pharma Technologist.com: Best Foam Forward

Foamix presents Innovative Intra-Vaginal Foam Delivery for Gynecology

Foamix Signs R&D Collaboration and License Agreement with Dr. Reddy’s for the Development and Commercialization of Psoriasis Foam

YNET: Collaboration with Warner Chilcott on gynecologic treatment (article in Hebrew)

Warner Chilcott and Foamix Collaborate on Gynecologic Foam Product

Foamix and Intendis Sign License Agreement for the Development of a Dermatological Foam

Globes: Foamix collaborates with Warner Chilcott on acne treatment

Warner Chilcott and Foamix Collaborate on Foam Product for the Treatment of Acne


 
GyneFoamix™


Many vulvo-genital disorders require topical therapy which is done today using suppositories, creams and ointments. Due to the nature of the target site, such vehicle does not provide sufficient coverage of the afflicted area, and thus, their efficacy is insufficient.

GyneFoamix products, comprising gynecological drugs in expandable foam formulations are delivered into the vagina and upon release, cover the afflicted surface effectively, thus providing favorable therapeutic results.


GyneFoamix™ is useful for a variety of female disorders:
    Many drugs can be incorporated in the GyneFoamix foam vehicle, including:
    • Antifungals
    • Antibiotics
    • Steroids/hormones
    • Local anesthetics
    • Anticancer drugs
    • Drugs for labor enhancement

    Clear advantages vs. current therapy (see comparison table)
    • One step administration
    • Convenient insertion
    • Easy removal
    • Accurate dose
    • No leak
    • Effective area of contact
    • Any drug can be included - water soluble, oil soluble and suspension
    • Residence time can be controlled: bio-adhesion and phase change polymers


Partnering
Foamix has completed the development of a number of such products, which are ready for either marketing or advanced development, worldwide.

Foamix is actively seeking development and marketing partners for products from the GyneFoamix™ platform.